DE602007013920D1 - Fusionsproteine der tnf-superfamilie - Google Patents
Fusionsproteine der tnf-superfamilieInfo
- Publication number
- DE602007013920D1 DE602007013920D1 DE602007013920T DE602007013920T DE602007013920D1 DE 602007013920 D1 DE602007013920 D1 DE 602007013920D1 DE 602007013920 T DE602007013920 T DE 602007013920T DE 602007013920 T DE602007013920 T DE 602007013920T DE 602007013920 D1 DE602007013920 D1 DE 602007013920D1
- Authority
- DE
- Germany
- Prior art keywords
- fusion proteins
- tnf superfamily
- present
- fusion protein
- tnfsf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000005829 trimerization reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06017891A EP1894940A1 (en) | 2006-08-28 | 2006-08-28 | TNF superfamily fusion proteins |
| PCT/EP2007/007517 WO2008025516A2 (en) | 2006-08-28 | 2007-08-28 | Tnf superfamily fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602007013920D1 true DE602007013920D1 (de) | 2011-05-26 |
Family
ID=37836940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602007013920T Active DE602007013920D1 (de) | 2006-08-28 | 2007-08-28 | Fusionsproteine der tnf-superfamilie |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8147843B2 (https=) |
| EP (2) | EP1894940A1 (https=) |
| JP (1) | JP5274464B2 (https=) |
| AT (1) | ATE505481T1 (https=) |
| AU (1) | AU2007291490A1 (https=) |
| CA (2) | CA2860945C (https=) |
| DE (1) | DE602007013920D1 (https=) |
| WO (1) | WO2008025516A2 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2176288B1 (en) | 2007-07-10 | 2015-11-04 | Apogenix GmbH | Tnf superfamily collectin fusion proteins |
| EP2540740B1 (en) * | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
| US20110189194A1 (en) * | 2008-07-14 | 2011-08-04 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| DK2604693T3 (en) | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
| JP5844158B2 (ja) | 2009-01-09 | 2016-01-13 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | 三量体形成融合タンパク質 |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| AU2013295647B2 (en) | 2012-07-26 | 2018-02-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
| WO2014100913A1 (en) * | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
| NO2776305T3 (https=) | 2014-04-23 | 2018-01-27 | ||
| BR102014031185A8 (pt) * | 2014-12-12 | 2021-05-04 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp | proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer |
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| EP3076179A1 (en) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnosis and treatment of low grade gliomas |
| AU2016325482B2 (en) | 2015-09-23 | 2020-09-03 | Apogenix Ag | Anti-CD95L antibody |
| EP3374504B1 (en) * | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| BR112019013940A2 (pt) | 2017-01-06 | 2020-02-11 | Iovance Biotherapeutics, Inc. | Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica. |
| US20200224161A1 (en) | 2017-05-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| EP3664832B1 (en) * | 2017-08-11 | 2023-10-18 | The Board of Trustees of the University of Illinois | Truncated guinea pig l-asparaginase variants and methods of use |
| EP4501408A3 (en) | 2017-11-17 | 2025-04-09 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
| EP3714041A1 (en) | 2017-11-22 | 2020-09-30 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
| EP3724885A2 (en) | 2017-12-15 | 2020-10-21 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| SG11202006541UA (en) | 2018-01-08 | 2020-08-28 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells |
| CA3090795A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
| MA52667B1 (fr) | 2018-03-29 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie |
| US20210130779A1 (en) | 2018-04-27 | 2021-05-06 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US20220275043A1 (en) | 2018-07-17 | 2022-09-01 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
| CA3112599A1 (en) | 2018-09-20 | 2020-03-26 | Iovance Biotherapeutics, Inc. | Expansion of tils from cryopreserved tumor samples |
| US20230039976A1 (en) | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| TW202039831A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療 |
| TW202039830A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 |
| CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| JP7710372B2 (ja) | 2018-12-19 | 2025-07-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用 |
| US20220133795A1 (en) | 2019-03-01 | 2022-05-05 | Iovance Biotherapeutics, Inc. | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof |
| CA3134144A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Llc | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
| US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| JP2022553389A (ja) | 2019-10-25 | 2022-12-22 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用 |
| CA3162703A1 (en) | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| US12516291B2 (en) | 2019-12-11 | 2026-01-06 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same |
| JP7817937B2 (ja) | 2020-02-27 | 2026-02-19 | ターンストーン バイオロジクス コーポレイション | 腫瘍反応性ｔ細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物 |
| EP4146794A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性ｔ細胞的選擇 |
| JP2023538667A (ja) * | 2020-08-24 | 2023-09-08 | サノフィ パスツール インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２感染症に対するワクチン |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| TW202241468A (zh) | 2020-12-11 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者 |
| CA3202483A1 (en) | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| AU2022246174A1 (en) | 2021-03-25 | 2023-09-14 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| KR20240013766A (ko) * | 2021-05-27 | 2024-01-30 | 베이징 안신화이더 바이오텍. 씨오., 엘티디 | 2개의 trail 삼량체를 포함하는 수퍼-trail 분자 |
| US20240342285A1 (en) | 2021-07-28 | 2024-10-17 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| EP4404969A1 (en) | 2021-09-24 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| EP4430167A1 (en) | 2021-11-10 | 2024-09-18 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| US20250101380A1 (en) | 2022-01-28 | 2025-03-27 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2410525A1 (en) * | 2000-05-26 | 2001-11-29 | Mochida Pharmaceuticals Co., Ltd. | Fas ligand-fused proteins |
-
2006
- 2006-08-28 EP EP06017891A patent/EP1894940A1/en not_active Withdrawn
-
2007
- 2007-08-28 CA CA2860945A patent/CA2860945C/en not_active Expired - Fee Related
- 2007-08-28 WO PCT/EP2007/007517 patent/WO2008025516A2/en not_active Ceased
- 2007-08-28 US US12/439,486 patent/US8147843B2/en not_active Expired - Fee Related
- 2007-08-28 AU AU2007291490A patent/AU2007291490A1/en not_active Abandoned
- 2007-08-28 DE DE602007013920T patent/DE602007013920D1/de active Active
- 2007-08-28 JP JP2009525967A patent/JP5274464B2/ja not_active Expired - Fee Related
- 2007-08-28 AT AT07801940T patent/ATE505481T1/de not_active IP Right Cessation
- 2007-08-28 EP EP07801940A patent/EP2069392B1/en not_active Not-in-force
- 2007-08-28 CA CA2661599A patent/CA2661599C/en not_active Expired - Fee Related
-
2012
- 2012-02-23 US US13/403,826 patent/US8580273B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2860945A1 (en) | 2008-03-06 |
| JP5274464B2 (ja) | 2013-08-28 |
| EP2069392B1 (en) | 2011-04-13 |
| US20120148527A1 (en) | 2012-06-14 |
| WO2008025516A3 (en) | 2008-04-17 |
| EP1894940A1 (en) | 2008-03-05 |
| US8580273B2 (en) | 2013-11-12 |
| CA2860945C (en) | 2015-12-29 |
| CA2661599A1 (en) | 2008-03-06 |
| JP2010501191A (ja) | 2010-01-21 |
| WO2008025516A2 (en) | 2008-03-06 |
| CA2661599C (en) | 2015-06-09 |
| EP2069392A2 (en) | 2009-06-17 |
| US8147843B2 (en) | 2012-04-03 |
| AU2007291490A1 (en) | 2008-03-06 |
| ATE505481T1 (de) | 2011-04-15 |
| US20110027218A1 (en) | 2011-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE505481T1 (de) | Fusionsproteine der tnf-superfamilie | |
| WO2009007120A3 (en) | Tnf superfamily collectin fusion proteins | |
| WO2010003766A3 (en) | Multimeric tnf receptors | |
| WO2009068627A3 (en) | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same | |
| WO2008074867A3 (en) | Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use | |
| BR0315327A (pt) | Antagonistas de il-15 | |
| EP2604693A3 (en) | TNFSF single chain molecules | |
| DK1767546T3 (da) | Angiogenese-inhiberende kimært protein og dets anvendelse | |
| PH12015500806A1 (en) | Binding molecules to the human ox40 receptor | |
| WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
| NO20053872L (no) | Fusjonskonstruksjoner og anvendelse av disse for fremstilling av antistoffer med okt FC-reseptorbindingsaffinitet og effektorfunksjon. | |
| WO2008066752A8 (en) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir | |
| EA202092589A3 (ru) | Cxcr2-связывающие полипептиды | |
| BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
| UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
| UA100682C2 (ru) | АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ | |
| ATE533782T1 (de) | Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür | |
| NO20062886L (no) | IL-23 og dens reseptor, beslektede reagenser og fremgangsmater | |
| ECSP12011698A (es) | Anticuerpos cea | |
| WO2008077945A3 (en) | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies | |
| WO2010020766A3 (en) | Interleukin fusion polypeptides | |
| WO2008074839A3 (en) | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders | |
| MX2010003055A (es) | Nuevas citocinas aviares y secuencias geneticas que las codifican. | |
| CR20240493A (es) | Proteínas de fusión de hmpv de prefusión estabilizadas | |
| WO2005021578A3 (en) | A novel chimeric polypeptide and use thereof |